A novel glycolipid antigen for NKT cells that preferentially induces IFN-γ production

Journal of Immunology

Volumn 195, Issue 3, 2015, Pages 924-933

  Birkholz, Alysia M ^a,b   Girardi, Enrico ^a,f   Wingender, Gerhard ^a   Khurana, Archana ^a   Wang, Jing ^a   Zhao, Meng ^a   Zahner, Sonja ^a   Illarionov, Petr A ^c   Wen, Xiangshu ^d   Li, Michelle ^d   Yuan, Weiming ^d   Porcelli, Steven A ^e   Besra, Gurdyal S ^c   Zajonc, Dirk M ^a   Kronenberg, Mitchell ^a,b  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD1D ANTIGEN; DB06 1 GLYCOSPHINGOLIPID; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; UNCLASSIFIED DRUG; ALPHA-GALACTOSYLCERAMIDE; CD1D ANTIGEN, MOUSE; DB06-1 COMPOUND; GALACTOSYLCERAMIDE; GLYCOSPHINGOLIPID; IL10 PROTEIN, MOUSE; PROTEIN BINDING;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING KINETICS; CELL STIMULATION; CELLULAR IMMUNITY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOKINE RESPONSE; DENDRITIC CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPID ANALYSIS; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TH1 CELL; ANIMAL; BINDING SITE; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; CHEMISTRY; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION; METABOLISM;

ANIMALS; ANTIGENS, CD1D; BINDING SITES; CELLS, CULTURED; DENDRITIC CELLS; GALACTOSYLCERAMIDES; GLYCOSPHINGOLIPIDS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-12; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NATURAL KILLER T-CELLS; PROTEIN BINDING; TH1 CELLS;

EID: 84937679962     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1500070     Document Type: Article

References (66)

1. Berzins, S. P., M. J. Smyth, and A. G. Baxter. 2011. Presumed guilty: natural killer T cell defects and human disease. Nat. Rev. Immunol. 11: 131-142.
2. MacDonald, H. R., and M. P. Mycko. 2007. Development and selection of Valpha l4i NKT cells. Curr. Top. Microbiol. Immunol. 314: 195-212.
3. Barral, D. C., and M. B. Brenner. 2007. CD1 antigen presentation: how it works. Nat. Rev. Immunol. 7: 929-941.
4. Zajonc, D. M., C. Cantu, III, J. Mattner, D. Zhou, P. B. Savage, A. Bendelac, I. A. Wilson, and L. Teyton. 2005. Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor. Nat. Immunol. 6: 810-818.
5. Borg, N. A., K. S. Wun, L. Kjer-Nielsen, M. C. Wilce, D. G. Pellicci, R. Koh, G. S. Besra, M. Bharadwaj, D. I. Godfrey, J. McCluskey, and J. Rossjohn. 2007. CD1d-lipid-Antigen recognition by the semi-invariant NKT T-cell receptor. Nature 448: 44-49.
6. Lantz, O., and A. Bendelac. 1994. An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans. J. Exp. Med. 180: 1097-1106.
7. Morita, M., K. Motoki, K. Akimoto, T. Natori, T. Sakai, E. Sawa, K. Yamaji, Y. Koezuka, E. Kobayashi, and H. Fukushima. 1995. Structure-Activity relationship of alpha-galactosylceramides against B16-bearing mice. J. Med. Chem. 38: 2176-2187.
8. Spada, F. M., Y. Koezuka, and S. A. Porcelli. 1998. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J. Exp. Med. 188: 1529-1534.
9. Bendelac, A., P. B. Savage, and L. Teyton. 2007. The biology of NKT cells. Annu. Rev. Immunol. 25: 297-336.
10. Parekh, V. V., M. T. Wilson, D. Olivares-Villagómez, A. K. Singh, L. Wu, C.-R. Wang, S. Joyce, and L. Van Kaer. 2005. Glycolipid antigen induces longterm natural killer T cell anergy in mice. J. Clin. Invest. 115: 2572-2583.
11. Sullivan, B. A., and M. Kronenberg. 2005. Activation or anergy: NKT cells are stunned by alpha-galactosylceramide. J. Clin. Invest. 115: 2328-2329.
12. Sag, D., P. Krause, C. C. Hedrick, M. Kronenberg, and G. Wingender. 2014. IL-10-producing NKT10 cells are a distinct regulatory invariant NKT cell subset. J. Clin. Invest. 124: 3725-3740.
13. Sullivan, B. A., N. A. Nagarajan, G. Wingender, J. Wang, I. Scott, M. Tsuji, R. W. Franck, S. A. Porcelli, D. M. Zajonc, and M. Kronenberg. 2010. Mechanisms for glycolipid antigen-driven cytokine polarization by Valpha14i NKT cells. J. Immunol. 184: 141-153.
14. Smyth, M. J., N. Y. Crowe, D. G. Pellicci, K. Kyparissoudis, J. M. Kelly, K. Takeda, H. Yagita, and D. I. Godfrey. 2002. Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. Blood 99: 1259-1266.
15. Yu, K. O. A., and S. A. Porcelli. 2005. The diverse functions of CD1d-restricted NKT cells and their potential for immunotherapy. Immunol. Lett. 100: 42-55.
16. Brennan, P. J., M. Brigl, and M. B. Brenner. 2013. Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat. Rev. Immunol. 13: 101-117.
17. Yu, K. O., J. S. Im, A. Molano, Y. Dutronc, P. A. Illarionov, C. Forestier, N. Fujiwara, I. Arias, S. Miyake, T. Yamamura, et al. 2005. Modulation of CD1d-restricted NKT cell responses by using N-Acyl variants of alpha-galactosylceramides. Proc. Natl. Acad. Sci. USA 102: 3383-3388.
18. Schneiders, F. L., R. J. Scheper, B. M. von Blomberg, A. M. Woltman, H. L. Janssen, A. J. van den Eertwegh, H. M. Verheul, T. D. de Gruijl, and H. J. van der Vliet. 2011. Clinical experience with a-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection. Clin. Immunol. 140: 130-141.
19. Terabe, M., and J. A. Berzofsky. 2008. The role of NKT cells in tumor immunity. Adv. Cancer Res. 101: 277-348.
20. Franck, R. W., and M. Tsuji. 2006. Alpha-c-galactosylceramides: synthesis and immunology. Acc. Chem. Res. 39: 692-701.
21. Patel, O., G. Cameron, D. G. Pellicci, Z. Liu, H. S. Byun, T. Beddoe, J. McCluskey, R. W. Franck, A. R. Castaño, Y. Harrak, et al. 2011. NKT TCR recognition of CD1d-A-C-galactosylceramide. J. Immunol. 187: 4705-4713.
22. Arora, P., M. M. Venkataswamy, A. Baena, G. Bricard, Q. Li, N. Veerapen, R. Ndonye, J. J. Park, J. H. Lee, K.-C. Seo, et al. 2011. A rapid fluorescencebased assay for classification of iNKT cell activating glycolipids. J. Am. Chem. Soc. 133: 5198-5201.
23. Naidenko, O. V., J. K. Maher, W. A. Ernst, T. Sakai, R. L. Modlin, and M. Kronenberg. 1999. Binding and antigen presentation of ceramide-containing glycolipids by soluble mouse and human CD1d molecules. J. Exp. Med. 190: 1069-1080.
24. Sidobre, S., K. J. Hammond, L. Bénazet-Sidobre, S. D. Maltsev, S. K. Richardson, R. M. Ndonye, A. R. Howell, T. Sakai, G. S. Besra, S. A. Porcelli, and M. Kronenberg. 2004. The T cell antigen receptor expressed by Valpha14i NKT cells has a unique mode of glycosphingolipid antigen recognition. Proc. Natl. Acad. Sci. USA 101: 12254-12259.
25. Tupin, E., and M. Kronenberg. 2006. Activation of natural killer T cells by glycolipids. Methods Enzymol. 417: 185-201.
26. Brossay, L., S. Tangri, M. Bix, S. Cardell, R. Locksley, and M. Kronenberg. 1998. Mouse CD1-Autoreactive T cells have diverse patterns of reactivity to CD1 + targets. J. Immunol. 160: 3681-3688.
27. Inaba, K., W. J. Swiggard, R. M. Steinman, N. Romani, G. Schuler, and C. Brinster. 2009. Isolation of dendritic cells. Curr. Protoc. Immunol. 86: 3.7.1-3.7.19.
28. Lawton, A. P., T. I. Prigozy, L. Brossay, B. Pei, A. Khurana, D. Martin, T. Zhu, K. Späte, M. Ozga, S. Höning, et al. 2005. The mouse CD1d cytoplasmic tail mediates CD1d trafficking and antigen presentation by adaptor protein 3-dependent and -independent mechanisms. J. Immunol. 174: 3179-3186.
29. Rogers, P. R., A. Matsumoto, O. Naidenko, M. Kronenberg, T. Mikayama, and S. Kato. 2004. Expansion of human Valpha24+ NKT cells by repeated stimulation with KRN7000. J. Immunol. Methods 285: 197-214.
30. Chiu, Y.-H., S.-H. Park, K. Benlagha, C. Forestier, J. Jayawardena-Wolf, P. B. Savage, L. Teyton, and A. Bendelac. 2002. Multiple defects in antigen presentation and T cell development by mice expressing cytoplasmic tailtruncated CD1d. Nat. Immunol. 3: 55-60.
31. Caton, M. L., M. R. Smith-Raska, and B. Reizis. 2007. Notch-RBP-J signaling controls the homeostasis of CD8- dendritic cells in the spleen. J. Exp. Med. 204: 1653-1664.
32. Wen, X., P. Rao, L. J. Carreño, S. Kim, A. Lawrenczyk, S. A. Porcelli, P. Cresswell, and W. Yuan. 2013. Human CD1d knock-in mouse model demonstrates potent antitumor potential of human CD1d-restricted invariant natural killer T cells. Proc. Natl. Acad. Sci. USA 110: 2963-2968.
33. Capone, M., D. Cantarella, J. Schümann, O. V. Naidenko, C. Garavaglia, F. Beermann, M. Kronenberg, P. Dellabona, H. R. MacDonald, and G. Casorati. 2003. Human invariant V alpha 24-J alpha Q TCR supports the development of CD1d-dependent NK1.1+ and NK1.12 T cells in transgenic mice. J. Immunol. 170: 2390-2398.
34. Tyznik, A. J., E. Tupin, N. A. Nagarajan, M. J. Her, C. A. Benedict, and M. Kronenberg. 2008. Cutting edge: the mechanism of invariant NKT cell responses to viral danger signals. J. Immunol. 181: 4452-4456.
35. Matsuda, J. L., O. V. Naidenko, L. Gapin, T. Nakayama, M. Taniguchi, C.-R. Wang, Y. Koezuka, and M. Kronenberg. 2000. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J. Exp. Med. 192: 741-754.
36. Zajonc, D. M., I. Maricic, D. Wu, R. Halder, K. Roy, C.-H. Wong, V. Kumar, and I. A. Wilson. 2005. Structural basis for CD1d presentation of a sulfatide derived from myelin and its implications for autoimmunity. J. Exp. Med. 202: 1517-1526.
37. Wang, J., Y. Li, Y. Kinjo, T. T. Mac, D. Gibson, G. F. Painter, M. Kronenberg, and D. M. Zajonc. 2010. Lipid binding orientation within CD1d affects recognition of Borrelia burgorferi antigens by NKT cells. Proc. Natl. Acad. Sci. USA 107: 1535-1540.
38. Matulis, G., J. P. Sanderson, N. M. Lissin, M. B. Asparuhova, G. R. Bommineni, D. Schümperli, R. R. Schmidt, P. M. Villiger, B. K. Jakobsen, and S. D. Gadola. 2010. Innate-like control of human iNKT cell autoreactivity via the hypervariable CDR3beta loop. PLoS Biol. 8: e1000402.
39. Pellicci, D. G., A. J. Clarke, O. Patel, T. Mallevaey, T. Beddoe, J. Le Nours, A. P. Uldrich, J. McCluskey, G. S. Besra, S. A. Porcelli, et al. 2011. Recognition of b-linked self glycolipids mediated by natural killer T cell antigen receptors. Nat. Immunol. 12: 827-833.
40. Gadola, S. D., M. Koch, J. Marles-Wright, N. M. Lissin, D. Shepherd, G. Matulis, K. Harlos, P. M. Villiger, D. I. Stuart, B. K. Jakobsen, et al. 2006. Structure and binding kinetics of three different human CD1d-Alphagalactosylceramide-specific T cell receptors. J. Exp. Med. 203: 699-710.
41. Leslie, A. G. 2006. The integration of macromolecular diffraction data. Acta Crystallogr. D Biol. Crystallogr. 62: 48-57.
42. Zajonc, D. M., P. B. Savage, A. Bendelac, I. A. Wilson, and L. Teyton. 2008. Crystal structures of mouse CD1d-iGb3 complex and its cognate Valpha14 T cell receptor suggest a model for dual recognition of foreign and self glycolipids. J. Mol. Biol. 377: 1104-1116.
43. Aspeslagh, S., Y. Li, E. D. Yu, N. Pauwels, M. Trappeniers, E. Girardi, T. Decruy, K. Van Beneden, K. Venken, M. Drennan, et al. 2011. Galactosemodified iNKT cell agonists stabilized by an induced fit of CD1d prevent tumour metastasis. EMBO J. 30: 2294-2305.
44. Emsley, P., B. Lohkamp, W. G. Scott, and K. Cowtan. 2010. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66: 486-501.
45. Lovell, S. C., I. W. Davis, W. B. Arendall, III, P. I. de Bakker, J. M. Word, M. G. Prisant, J. S. Richardson, and D. C. Richardson. 2003. Structure validation by Calpha geometry: phi,psi and Cbeta deviation. Proteins 50: 437-450.
46. Carnaud, C., D. Lee, O. Donnars, S. H. Park, A. Beavis, Y. Koezuka, and A. Bendelac. 1999. Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J. Immunol. 163: 4647-4650.
47. Kawakami, K., Y. Kinjo, S. Yara, Y. Koguchi, K. Uezu, T. Nakayama, M. Taniguchi, and A. Saito. 2001. Activation of Valpha14(+) natural killer T cells by alpha-galactosylceramide results in development of Th1 response and local host resistance in mice infected with Cryptococcus neoformans. Infect. Immun. 69: 213-220.
48. Kitamura, H., K. Iwakabe, T. Yahata, S. Nishimura, A. Ohta, Y. Ohmi, M. Sato, K. Takeda, K. Okumura, L. Van Kaer, et al. 1999. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J. Exp. Med. 189: 1121-1128.
49. Parekh, V. V., A. K. Singh, M. T. Wilson, D. Olivares-Villagómez, J. S. Bezbradica, H. Inazawa, H. Ehara, T. Sakai, I. Serizawa, L. Wu, et al. 2004. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha- and beta-Anomeric glycolipids. J. Immunol. 173: 3693-3706.
50. Tyznik, A. J., S. Verma, Q. Wang, M. Kronenberg, and C. A. Benedict. 2014. Distinct requirements for activation of NKT and NK cells during viral infection. J. Immunol. 192: 3676-3685.
51. Arora, P., A. Baena, K. O. Yu, N. K. Saini, S. S. Kharkwal, M. F. Goldberg, S. Kunnath-Velayudhan, L. J. Carreño, M. M. Venkataswamy, J. Kim, et al. 2014. A single subset of dendritic cells controls the cytokine bias of natural killer T cell responses to diverse glycolipid antigens. Immunity 40: 105-116.
52. Barral, P., P. Polzella, A. Bruckbauer, N. van Rooijen, G. S. Besra, V. Cerundolo, and F. D. Batista. 2010. CD169(+) macrophages present lipid antigens to mediate early activation of iNKT cells in lymph nodes. Nat. Immunol. 11: 303-312.
53. Tyznik, A. J., E. Farber, E. Girardi, A. Birkholz, Y. Li, S. Chitale, R. So, P. Arora, A. Khurana, J. Wang, et al. 2011. Glycolipids that elicit IFN-g-biased responses from natural killer T cells. Chem. Biol. 18: 1620-1630.
54. Prigozy, T. I., O. Naidenko, P. Qasba, D. Elewaut, L. Brossay, A. Khurana, T. Natori, Y. Koezuka, A. Kulkarni, and M. Kronenberg. 2001. Glycolipid antigen processing for presentation by CD1d molecules. Science 291: 664-667.
55. Oki, S., A. Chiba, T. Yamamura, and S. Miyake. 2004. The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells. J. Clin. Invest. 113: 1631-1640.
56. Rossjohn, J., D. G. Pellicci, O. Patel, L. Gapin, and D. I. Godfrey. 2012. Recognition of CD1d-restricted antigens by natural killer T cells. Nat. Rev. Immunol. 12: 845-857.
57. Lynch, L., X. Michelet, S. Zhang, P. J. Brennan, A. Moseman, C. Lester, G. Besra, E. E. Vomhof-Dekrey, M. Tighe, H.-F. Koay, et al. 2015. Regulatory iNKT cells lack expression of the transcription factor PLZF and control the homeostasis of T(reg) cells and macrophages in adipose tissue. Nat. Immunol. 16: 85-95.
58. Padte, N. N., M. Boente-Carrera, C. D. Andrews, J. McManus, B. F. Grasperge, A. Gettie, J. G. Coelho-dos-Reis, X. Li, D. Wu, J. T. Bruder, et al. 2013. A glycolipid adjuvant, 7DW8-5, enhances CD8+ T cell responses induced by an adenovirus-vectored malaria vaccine in non-human primates. PLoS ONE 8: e78407.
59. Uchida, T., S. Horiguchi, Y. Tanaka, H. Yamamoto, N. Kunii, S. Motohashi, M. Taniguchi, T. Nakayama, and Y. Okamoto. 2008. Phase I study of a-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer. Cancer Immunol. Immunother. 57: 337-345.
60. Bai, L., M. G. Constantinides, S. Y. Thomas, R. Reboulet, F. Meng, F. Koentgen, L. Teyton, P. B. Savage, and A. Bendelac. 2012. Distinct APCs explain the cytokine bias of a-galactosylceramide variants in vivo. J. Immunol. 188: 3053-3061.
61. Lalazar, G., A. Ben Ya'acov, N. Eliakim-Raz, D. M. Livovsky, O. Pappo, S. Preston, L. Zolotarov, and Y. Ilan. 2008. Beta-glycosphingolipids-mediated lipid raft alteration is associated with redistribution of NKT cells and increased intrahepatic CD8+ T lymphocyte trapping. J. Lipid Res. 49: 1884-1893.
62. Aspeslagh, S., M. Nemcovic, N. Pauwels, K. Venken, J. Wang, S. Van Calenbergh, D. M. Zajonc, and D. Elewaut. 2013. Enhanced TCR footprint by a novel glycolipid increases NKT-dependent tumor protection. J. Immunol. 191: 2916-2925.
63. Singh, A. K., M. T. Wilson, S. Hong, D. Olivares-Villagómez, C. Du, A. K. Stanic, S. Joyce, S. Sriram, Y. Koezuka, and L. Van Kaer. 2001. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J. Exp. Med. 194: 1801-1811.
64. Jahng, A. W., I. Maricic, B. Pedersen, N. Burdin, O. Naidenko, M. Kronenberg, Y. Koezuka, and V. Kumar. 2001. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J. Exp. Med. 194: 1789-1799.
65. Furlan, R., A. Bergami, D. Cantarella, E. Brambilla, M. Taniguchi, P. Dellabona, G. Casorati, and G. Martino. 2003. Activation of invariant NKT cells by alphaGalCer administration protects mice from MOG35-55-induced EAE: critical roles for administration route and IFN-gamma. Eur. J. Immunol. 33: 1830-1838.
66. Miellot, A., R. Zhu, S. Diem, M. C. Boissier, A. Herbelin, and N. Bessis. 2005. Activation of invariant NK T cells protects against experimental rheumatoid arthritis by an IL-10-dependent pathway. Eur. J. Immunol. 35: 3704-3713.